anonymous
Guest
anonymous
Guest
The restructure is underway in International Business. Legacy product lines remain strong, the rest is dragging the business down.
The switch has already been thrown & the lights are out for many planned launches.
I am sure the shareholders will be pleased as it is dressed up as strong leadership. They will blame market factors, political upheaval & many other crazy things. The facts are, the products are weak & in a competitive therapy. But like everything in NEW Allergan too many people work in silos and are not willing to call out when the numbers don't add up. The last few years the business has been about politics and getting to the top quicker! Brent is able to talk his way out of things...for now, but slowly Allergan is going the wrong way.
The switch has already been thrown & the lights are out for many planned launches.
I am sure the shareholders will be pleased as it is dressed up as strong leadership. They will blame market factors, political upheaval & many other crazy things. The facts are, the products are weak & in a competitive therapy. But like everything in NEW Allergan too many people work in silos and are not willing to call out when the numbers don't add up. The last few years the business has been about politics and getting to the top quicker! Brent is able to talk his way out of things...for now, but slowly Allergan is going the wrong way.